双靶向MAPK/VEGF抑制治疗KRAS突变脑动静脉畸形
研究利用可滴定KRASG12V-GFP转基因小鼠模型,发现脑内皮细胞选择性过表达KRASG12V可剂量依赖性形成bAVM并增加出血负担、降低生存。在已形成出血性bAVM的小鼠中,单用MEK抑制剂trametinib modestly改善中位生存(8.4 vs 6.4周,p=0.049),单用抗VEGF治疗反而降低生存(6.9 vs 9.6周,p=0.044),而trametinib或RMC-7977联合抗VEGF显著延长生存,其中RMC-7977联合抗VEGF组获益最显著(13.1 vs 6.7周,p=0.024)。
要点
- 脑内皮KRASG12V过表达剂量依赖性促进bAVM形成和出血。
- 单用抗VEGF治疗在出血性bAVM模型中降低生存。
- MAPK与VEGF通路联合抑制显著延长生存。
核心结论
- 脑内皮细胞KRAS突变除促进bAVM形成外,可能因果性参与bAVM破裂。
- 联合抑制MAPK和VEGF通路可能是KRAS突变bAVM有前景的新治疗策略。
研究设计与样本
- 使用可滴定KRASG12V-GFP转基因工程小鼠模型。
- 通过AAV-BR1-CAG载体将KRASG12V-GFP特异性递送至脑内皮细胞,剂量为5×10^7至5×10^10基因组拷贝。
- 评估bAVM形成、脑出血和总生存;病毒递送4周后对已形成出血性bAVM的小鼠给予trametinib或RMC-7977,联合或不联合抗小鼠VEGF抗体。
主要发现
- 脑内皮细胞选择性过表达KRASG12V-GFP剂量依赖性导致bAVM形成。
- 最高转基因剂量组bAVM数量显著增多、脑出血负担更高、总生存更差。
- 最高剂量组中,trametinib单药 modestly改善中位总生存(8.4周 vs 6.4周,p=0.049),RMC-7977单药无显著获益。
- 抗VEGF单药降低生存(6.9周 vs 9.6周,p=0.044)。
- trametinib或RMC-7977联合抗VEGF抗体显著延长生存,RMC-7977联合抗VEGF组获益最显著(13.1周 vs 对照组6.7周,p=0.024)。
临床怎么用
- 提示对KRAS突变bAVM患者,单纯抗VEGF治疗可能有害。
- 联合MAPK和VEGF通路抑制可能成为KRAS突变bAVM的潜在治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Brain arteriovenous malformations (bAVMs) are rare but potentially devastating cerebrovascular lesions. Activating KRAS mutations are common in sporadic bAVMs, but their clinical implications remain unclear. The aim of this study was to investigate a novel therapeutic strategy for hemorrhagic bAVMs based on dual inhibition of the mitogen-activated protein kinase (MAPK) and vascular endothelial growth factor (VEGF) pathways using an engineered mouse model with a titratable KRASG12V-GFP transgene. METHODS: The AAV-BR1-CAG vector was used to deliver a KRASG12V-GFP transgene specifically to cerebral endothelial cells. Mice received 5 × 107 to 5 × 1010 genome copies of the vector, and bAVM formation, intracerebral hemorrhage (ICH), and overall survival were assessed. Mice with established hemorrhagic bAVMs were subsequently treated with trametinib (MEK inhibitor) or RMC-7977 (RAS inhibitor), with or without an anti-mouse VEGF antibody, starting 4 weeks after viral delivery. Overall survival was assessed. RESULTS: Selective overexpression of KRASG12V-GFP in cerebral endothelial cells led to the formation of bAVMs in a dose-dependent manner. Mice that received the highest transgene dose developed significantly more bAVMs, exhibited a higher ICH burden, and had worse overall survival compared with those that received lower transgene doses. In mice receiving the highest transgene dose, trametinib alone modestly improved the median overall survival (8.4 weeks vs 6.4 weeks, p = 0.049), while single-agent RMC-7977 showed no significant benefit. Anti-VEGF therapy alone reduced survival (6.9 weeks vs 9.6 weeks, p = 0.044). However, combination therapy with trametinib or RMC-7977 and anti-VEGF antibody significantly prolonged survival, with the most pronounced benefit seen in the RMC-7977 plus anti-VEGF group (13.1 weeks vs 6.7 weeks in controls, p = 0.024). CONCLUSIONS: Our findings suggest that, in addition to promoting bAVM formation, KRAS mutations in cerebral endothelial cells might be causally implicated in bAVM rupture. Additionally, concomitant inhibition of the MAPK and VEGF pathways could be a promising novel therapeutic strategy for KRAS-mutated bAVMs.
引用
- Naylor RM, Ueki Y, Alsereidi FR, et al. Dual MAPK/VEGF inhibition for KRAS-mutated brain arteriovenous malformations. J Neurosurg. 2025. PMID: 41172372. doi:10.3171/2025.7.JNS25708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。